8-K: Actuate Therapeutics Secures $4.7 Million in Private Placement to Fund Operations, Addresses Going Concern Risk

Actuate Therapeutics, Inc. has entered into a private placement agreement to issue common stock and warrants, raising approximately $4.7 million in gross proceeds to support its working capital and general corporate purposes, while acknowledging a 'going concern' risk.

Summary

• Actuate Therapeutics, Inc. entered into a Securities Purchase Agreement on June 25, 2025, for a private placement with institutional and accredited investors.
• The company agreed to issue and sell 666,497 shares of common stock at a purchase price of $7.00 per share.
• Warrants to purchase up to an aggregate of 666,497 shares of common stock were also issued, with an exercise price of $7.00 per warrant.
• The warrants are exercisable on a cash-only basis and expire 20 days following the 'Milestone Date'.
• The 'Milestone Date' is defined as the earliest of (i) FDA issuing Breakthrough Therapy designation for elraglusib or (ii) FDA providing written communication on pursuing registration for elraglusib using Phase 2 or Phase 3 clinical data.
• The private placement is expected to generate approximately $4.7 million in gross proceeds, with potential for an additional $4.7 million if all warrants are exercised.
• Net proceeds from this financing are intended for working capital and general corporate purposes.
• The company also entered into a Registration Rights Agreement on June 25, 2025, committing to file a registration statement for the resale of the shares and warrant shares by August 9, 2025.
• A current stockholder, Bios 2024 Co-Invest, LP, which will beneficially own approximately 49.9% of the company's common stock (including warrants) post-closing, participated in the private placement, purchasing 71,428 shares and warrants for $499,996.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company explicitly states a 'going concern' risk, the successful securing of a capital raise, even if necessary, provides a lifeline and funds for continued operations and drug development. The participation of a significant existing investor also adds a layer of confidence. However, the underlying financial fragility and the inherent risks of drug development temper the overall positivity.

Positives

• The private placement secures approximately $4.7 million in gross proceeds, providing crucial working capital and funds for general corporate purposes.
• The potential for an additional $4.7 million upon full exercise of warrants offers a future funding source tied to key clinical milestones.
• The participation of a significant existing institutional investor (Bios 2024 Co-Invest, LP) demonstrates continued support and confidence in the company.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• The company's financial condition raises 'substantial doubt as to our ability to continue as a going concern', indicating significant financial challenges.
• The need for additional capital to finance operations for fiscal year 2025 highlights ongoing funding requirements.

Risks

• Preliminary and unpublished clinical data may be subject to change and further interpretation, and should not be relied upon as a final analysis.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities and within the medical community.
• Clinical and preclinical drug development is a lengthy and expensive process with uncertain timelines and outcomes.
• Results of prior preclinical studies and early clinical trials are not necessarily predictive of future results.
• Elraglusib may not achieve positive clinical results or favorable preclinical results, potentially delaying or preventing regulatory submissions or approvals.
• The company may not successfully enroll additional patients or establish/advance plans for further development, including through conversations with the FDA or EMA.
• Elraglusib could be associated with side effects, adverse events, or other safety risks, which could delay or preclude regulatory approval, cause suspension/discontinuation of clinical trials, or result in other negative consequences.
• Reliance on third parties to conduct non-clinical studies and clinical trials poses operational risks.
• Reliance on third-party licensors and the ability to preserve and protect intellectual property rights are critical.
• Significant competition from other biotechnology and pharmaceutical companies could impact market position and success.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern, and a failure to obtain necessary capital could force delays, reductions, or termination of development programs or commercialization efforts.
• The amount of proceeds expected from the Private Placement, and the timing and certainty of its completion, are subject to customary closing conditions and inherent uncertainties.
• The filing of a registration statement to register for resale the Registrable Securities being sold in connection with the private placement is subject to SEC review and effectiveness timelines.

Future Outlook

The company anticipates using the net proceeds from this financing for working capital and general corporate purposes. It is committed to filing a registration statement for the resale of the newly issued securities by August 9, 2025, and to use reasonable efforts to ensure its effectiveness. The exercise of warrants is tied to the 'Milestone Date,' which is the earliest of the FDA issuing Breakthrough Therapy designation for elraglusib or providing written communication on pursuing registration for elraglusib using Phase 2 or Phase 3 clinical data. The company acknowledges that its financial condition raises substantial doubt about its ability to continue as a going concern and that it requires additional capital for fiscal year 2025 operations.

Management Comments

• Daniel Schmitt, President and Chief Executive Officer, signed the 8-K report on behalf of Actuate Therapeutics, Inc.

Industry Context

This private placement is a common financing mechanism for biotechnology companies, particularly those in clinical development stages like Actuate Therapeutics, Inc. The reliance on a 'Milestone Date' tied to FDA designations (Breakthrough Therapy) or regulatory pathway decisions (Phase 2/3 data for registration) for warrant exercise is typical for biotech firms seeking to align investor incentives with key drug development progress. The stated 'going concern' risk is a significant red flag in the biotech industry, often necessitating such capital raises to fund lengthy and expensive clinical trials and operational costs, especially given the uncertain timelines and outcomes inherent in drug development. The participation of a major existing institutional investor, Bios 2024 Co-Invest, LP, is a positive signal of continued support, which can be crucial for a company facing financial challenges and intense competition.

Legal Proceedings

• There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to the Company's knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.

Related Party Transactions

• Bios 2024 Co-Invest, LP, a current stockholder and affiliate of the Company, agreed to purchase 71,428 shares and warrants to purchase 71,428 shares in the Private Placement for an aggregate purchase price of $499,996.
• Following the closing, Bios 2024 Co-Invest, LP, together with its affiliates, is deemed to beneficially own approximately 49.9% of the Company's Common Stock, including the Warrants and other rights to acquire Common Stock.
• Dr. Aaron G.L. Fletcher, Founder and President of Bios Research, is the Chairman of the Company's Board of Directors.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and potential future warrant exercises, but the capital raise addresses the 'going concern' risk, potentially stabilizing the company's financial position and allowing continued operations.
• Employees: The capital raise provides funding for continued operations, reducing immediate job security concerns related to the 'going concern' warning.
• Customers/Patients (future): Continued funding supports the development of elraglusib, potentially leading to future therapeutic options.
• Creditors: The capital raise improves the company's liquidity and ability to meet its financial obligations, potentially reducing credit risk.

Next Steps

• Closing of the private placement on or before June 30, 2025.
• Company to prepare and file an initial Registration Statement covering the resale of all Registrable Securities by August 9, 2025.
• Company to use reasonable efforts to cause the registration statement to become effective by the earlier of 90 calendar days (if SEC review) or 5 business days (if no SEC review) following filing.
• Company to use reasonable efforts to keep the registration statement continuously effective until all Registrable Securities are resold or eligible for Rule 144 without restrictions.
• FDA's determination regarding Breakthrough Therapy designation for elraglusib or written communication on pursuing registration for elraglusib using Phase 2 or Phase 3 clinical data, which will trigger the 'Milestone Date' for warrant exercise.

Key Dates

Keywords

Private Placement, Warrants, Common Stock, SEC Filing, Biotechnology, Pharmaceutical, Clinical Trials, FDA, Elraglusib, Going Concern, Capital Raise, Registration Rights, Drug Development, Corporate Finance